[go: up one dir, main page]

WO1996039504A3 - Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede - Google Patents

Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede Download PDF

Info

Publication number
WO1996039504A3
WO1996039504A3 PCT/EP1996/002461 EP9602461W WO9639504A3 WO 1996039504 A3 WO1996039504 A3 WO 1996039504A3 EP 9602461 W EP9602461 W EP 9602461W WO 9639504 A3 WO9639504 A3 WO 9639504A3
Authority
WO
WIPO (PCT)
Prior art keywords
metastatic
methods
polynucleotides
polypeptides
distinguishing
Prior art date
Application number
PCT/EP1996/002461
Other languages
English (en)
Other versions
WO1996039504A2 (fr
Inventor
Emilay Shtivelman
Adam Sampson-Johannes
Original Assignee
Sandoz Ltd
Systemix Inc
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd, Systemix Inc, Sandoz Ag filed Critical Sandoz Ltd
Priority to AU63008/96A priority Critical patent/AU6300896A/en
Publication of WO1996039504A2 publication Critical patent/WO1996039504A2/fr
Publication of WO1996039504A3 publication Critical patent/WO1996039504A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des séquences nucléotidiques codant un nouvel ADN complémentaire classique spécifique du carcinome à petites cellules du poumon, la séquence d'acides aminés de la protéine correspondante, des procédés permettant l'expression et la purification de cette protéine, des anticorps dirigés contre cette protéine ainsi que leurs procédés d'utilisation.
PCT/EP1996/002461 1995-06-06 1996-06-06 Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede WO1996039504A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63008/96A AU6300896A (en) 1995-06-06 1996-06-06 Methods for distinguishing metastatic and non-metastatic cancers, polynucleotides and polypeptides for use therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47172395A 1995-06-06 1995-06-06
US08/471,723 1995-06-06

Publications (2)

Publication Number Publication Date
WO1996039504A2 WO1996039504A2 (fr) 1996-12-12
WO1996039504A3 true WO1996039504A3 (fr) 1997-01-09

Family

ID=23872750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002461 WO1996039504A2 (fr) 1995-06-06 1996-06-06 Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede

Country Status (2)

Country Link
AU (1) AU6300896A (fr)
WO (1) WO1996039504A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060116A1 (fr) * 1998-05-18 1999-11-25 Roche Diagnostics Gmbh Acide nucleique a regulation negative de la metastase (drim) codant pour une proteine, et utilisation diagnostique et therapeutique de cet acide nucleique
WO2005007692A1 (fr) * 2003-07-11 2005-01-27 Uab Research Foundation Anticorps qui reconnaissent la proteine brms1 et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000757A1 (fr) * 1990-07-09 1992-01-23 Research Corporation Technologies, Inc. Diagnostic du cancer metastatique a l'aide du gene mts-1
WO1994001777A1 (fr) * 1992-07-14 1994-01-20 Michigan Cancer Foundation Procede pour determiner le potentiel metastatique de cellules tumorales
WO1994020147A1 (fr) * 1993-03-04 1994-09-15 Systemix, Inc. Modele de metastase chez de petits animaux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000757A1 (fr) * 1990-07-09 1992-01-23 Research Corporation Technologies, Inc. Diagnostic du cancer metastatique a l'aide du gene mts-1
WO1994001777A1 (fr) * 1992-07-14 1994-01-20 Michigan Cancer Foundation Procede pour determiner le potentiel metastatique de cellules tumorales
WO1994020147A1 (fr) * 1993-03-04 1994-09-15 Systemix, Inc. Modele de metastase chez de petits animaux

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
8TH INTERNATIONAL CONGRESS OF IMMUNOLOGY, Budapest, Hungary, August 23-28, 1992 Springer-Verlag Budapest See M.SALMI ET AL.: Expression of domain 3 *
EMBL DATABASE, Accession number T72319 Sequence reference HS31940 from human cDNA clone 85879;17 March 1995 *
EMBL DATABASE, Accession number T96211 Sequence reference HS21168 from human cDNA clone 120965;14 April 1995 *
POLLOCK ET AL.: "Cloning, sequencing, and expression of the gene encoding the high-molecular-weight Cytochrome c from Desulfovibrio vulgaris Hildenborough", JOURNAL OF BACTERIOLOGY, vol. 173, no. 1, January 1991 (1991-01-01), pages 220 - 228, XP000609018 *
S.SEITER ET AL.: "Prevention of tumor metastasis formation by anti-variant CD44", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 177, no. 2, 1 February 1993 (1993-02-01), NEW YORK US, pages 443 - 455, XP002018001 *

Also Published As

Publication number Publication date
WO1996039504A2 (fr) 1996-12-12
AU6300896A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
EP0258411A4 (fr) Adn codant la streptavidine, spreptavidine ainsi produite, polypeptides fusionnes comprenant des sequences d'acides amines presents dans la streptavidine et leurs utilisations.
CA2263889A1 (fr) Proteines ligands de p-selectine
AU2681497A (en) Novel agouti-related gene
WO2000008057A3 (fr) Molecules designees b7l-1
HU9601448D0 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
IL193886A (en) Antibodies that bind to ldcam sequences
WO2000006738A3 (fr) Acides nucleiques et proteines de streptococcus pneumoniae
WO1998021343A8 (fr) Genes codant des proteines de telomerase
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
WO1993018146A3 (fr) Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques
CA2302147A1 (fr) Procedes d'analyse de proteines
CA2336261A1 (fr) Genes et proteines cycline e2
WO1995030001A3 (fr) Nouvelle proteine ligand de p-selectine
EP1117779A4 (fr) PROTEINE $i(MORAXELLA CATARRHALIS), SEQUENCE D'ACIDE NUCLEIQUE ET UTILISATIONS DE CELLES-CI
AU2462399A (en) Cubilin protein, dna sequences encoding cubilin and uses thereof
HUP0300851A3 (en) Purified proteins, recombinant dna sequences and processes for producing caffeine free beverages
WO1996039504A3 (fr) Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede
WO2000020450A3 (fr) Gene alpha-2/delta
GB9421093D0 (en) Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
EP0816498A3 (fr) Récepteur pour acide aminé excitateur et acides nucléiques liés
TW342413B (en) Novel toxins isolated from Bracon Hebetor
WO2001087932A3 (fr) Sept protéines transmembranaires et polynucléotides les codant
CA2311646A1 (fr) Gene tsa305
WO2001049714A3 (fr) Polypeptides nope, acides nucleiques les codant, et modes d'utilisation
WO1996038556A3 (fr) Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA